The patent will protect the Elite’s proprietary formulation for abuse resistant products utilizing the pharmacological approach.
Elite, which develops oral sustained and controlled release products, has additional patents pending for its technology.
Elite Pharmaceuticals chairman and CEO said, "The issuance of this patent is an important milestone for the company. It validates our pharmacological approach to the development of abuse-resistant drug products and provides additional value for these products."